{"id":{"repo_id":"missouri","oai_identifier":"oai:mospace.umsystem.edu:10355/10921"},"canonical_url":"https://search.dev.ndltd.org/etd/missouri/oai:mospace.umsystem.edu:10355/10921","repository":{"repo_id":"missouri","name":"University of Missouri","base_url":"https://mospace.umsystem.edu/oai/request"},"display":{"title":"Targeting the bombesin subtype 2 receptor for the diagnosis and treatment of metastatic prostate cancer","abstract":"[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT AUTHOR'S REQUEST.] In the United States, prostate cancer is the most commonly diagnosed cancer and the third leading cause of cancer related deaths in men. With early detection, definitive therapeutic options can provide a cure. However, undetected extracapsular or regional lymph node metastasis plagues the long-term survival statistics of definitive therapies. In advanced prostate cancer, initial androgen depravation therapy has failed to control cancer progression, and regional lymph node and distant osseous metastasis are common. With metastatic spread, prostate cancer remains incurable. Aberrant expression of the bombesin subtype 2 receptor (BB2r) is present on over 80% of human prostate cancer tissues evaluated. The BB2r binds with high affinity to the bombesin peptide (BBN), stimulating agonist mediated receptor-peptide internalization into the cancer cell. Accordingly, targeting the BB2r with radioisotopes conjugated to BBN represents a promising method for diagnostic and therapeutic radiopharmaceutical development for metastatic prostate cancer. The results of this research demonstrate the potential diagnostic capabilities of BB2r targeted compounds. We also demonstrate a potential mechanism of therapeutic effect while optimizing administration timing, and evaluate the therapeutic potential of BB2r targeted radiotherapy administered with FDA approved, radiosensitizing chemotherapeutics for the treatment of metastatic prostate cancer. Taken together, BB2r targeted radiopharmaceuticals have the potential to fill a well known clinical need for the diagnosis and treatment of metastatic prostate cancer in human patients.","abstract_html":"[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT AUTHOR'S REQUEST.] In the United States, prostate cancer is the most commonly diagnosed cancer and the third leading cause of cancer related deaths in men. With early detection, definitive therapeutic options can provide a cure. However, undetected extracapsular or regional lymph node metastasis plagues the long-term survival statistics of definitive therapies. In advanced prostate cancer, initial androgen depravation therapy has failed to control cancer progression, and regional lymph node and distant osseous metastasis are common. With metastatic spread, prostate cancer remains incurable. Aberrant expression of the bombesin subtype 2 receptor (BB2r) is present on over 80% of human prostate cancer tissues evaluated. The BB2r binds with high affinity to the bombesin peptide (BBN), stimulating agonist mediated receptor-peptide internalization into the cancer cell. Accordingly, targeting the BB2r with radioisotopes conjugated to BBN represents a promising method for diagnostic and therapeutic radiopharmaceutical development for metastatic prostate cancer. The results of this research demonstrate the potential diagnostic capabilities of BB2r targeted compounds. We also demonstrate a potential mechanism of therapeutic effect while optimizing administration timing, and evaluate the therapeutic potential of BB2r targeted radiotherapy administered with FDA approved, radiosensitizing chemotherapeutics for the treatment of metastatic prostate cancer. Taken together, BB2r targeted radiopharmaceuticals have the potential to fill a well known clinical need for the diagnosis and treatment of metastatic prostate cancer in human patients.","abstract_has_math":false,"creators":["Manuel, Christopher Aaron, 1977-"],"institution":"University of Missouri--Columbia","degree_name":"Ph. D.","degree_level":"Doctoral","degree_discipline":"Veterinary pathobiology (MU)","degree_department":null,"school":null,"contributors":[],"advisors":["Hoffman, Timothy Joseph, 1958-"],"committee_chairs":[],"committee_members":[],"year":2010,"date_issued":"2010","date_published":"2010","updated_at":"2026-07-24T03:08:20Z","subjects":[],"languages":["eng","English"],"rights":["Access to files is limited to the campuses of the University of Missouri with SSO login."],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.doi","label":"DOI","values":["https://doi.org/10.32469/10355/10921"],"render_values":[{"text":"https://doi.org/10.32469/10355/10921","href":"https://doi.org/10.32469/10355/10921","code":true}]}]},"links":{"outbound_url":"https://hdl.handle.net/10355/10921","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Hoffman, Timothy Joseph, 1958-"]},{"key":"dc:creator","label":"Author","values":["Manuel, Christopher Aaron, 1977-"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2011-06-10T13:49:09Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2011-06-10T13:49:09Z"]},{"key":"dc:date.issued","label":"Date","values":["2010"]},{"key":"dc:publisher","label":"Institution","values":["University of Missouri--Columbia"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Veterinary pathobiology (MU)"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Doctoral"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph. D."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Missouri--Columbia"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["English"]},{"key":"dc:language.iso","label":"Language (ISO)","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["Access to files is limited to the campuses of the University of Missouri with SSO login."]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.doi","label":"DOI","values":["https://doi.org/10.32469/10355/10921"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/10355/10921"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["The entire dissertation/thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file (which also appears in the research.pdf); a non-technical general description, or public abstract, appears in the public.pdf file.","Title from PDF of title page (University of Missouri--Columbia, viewed on May 31, 2011).","Vita.","Thesis advisor: Timothy J. Hoffman.","\"May 2010\"","Ph. D. University of Missouri-Columbia 2010."]},{"key":"dc:description.abstract","label":"Abstract","values":["[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT AUTHOR'S REQUEST.] In the United States, prostate cancer is the most commonly diagnosed cancer and the third leading cause of cancer related deaths in men. With early detection, definitive therapeutic options can provide a cure. However, undetected extracapsular or regional lymph node metastasis plagues the long-term survival statistics of definitive therapies. In advanced prostate cancer, initial androgen depravation therapy has failed to control cancer progression, and regional lymph node and distant osseous metastasis are common. With metastatic spread, prostate cancer remains incurable. Aberrant expression of the bombesin subtype 2 receptor (BB2r) is present on over 80% of human prostate cancer tissues evaluated. The BB2r binds with high affinity to the bombesin peptide (BBN), stimulating agonist mediated receptor-peptide internalization into the cancer cell. Accordingly, targeting the BB2r with radioisotopes conjugated to BBN represents a promising method for diagnostic and therapeutic radiopharmaceutical development for metastatic prostate cancer. The results of this research demonstrate the potential diagnostic capabilities of BB2r targeted compounds. We also demonstrate a potential mechanism of therapeutic effect while optimizing administration timing, and evaluate the therapeutic potential of BB2r targeted radiotherapy administered with FDA approved, radiosensitizing chemotherapeutics for the treatment of metastatic prostate cancer. Taken together, BB2r targeted radiopharmaceuticals have the potential to fill a well known clinical need for the diagnosis and treatment of metastatic prostate cancer in human patients."]},{"key":"dc:title","label":"Title","values":["Targeting the bombesin subtype 2 receptor for the diagnosis and treatment of metastatic prostate cancer"]}]}],"canonical_facts":{"dc:contributor.advisor":["Hoffman, Timothy Joseph, 1958-"],"dc:creator":["Manuel, Christopher Aaron, 1977-"],"dc:date.accessioned":["2011-06-10T13:49:09Z"],"dc:date.available":["2011-06-10T13:49:09Z"],"dc:date.issued":["2010"],"dc:description":["The entire dissertation/thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file (which also appears in the research.pdf); a non-technical general description, or public abstract, appears in the public.pdf file.","Title from PDF of title page (University of Missouri--Columbia, viewed on May 31, 2011).","Vita.","Thesis advisor: Timothy J. Hoffman.","\"May 2010\"","Ph. D. University of Missouri-Columbia 2010."],"dc:description.abstract":["[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT AUTHOR'S REQUEST.] In the United States, prostate cancer is the most commonly diagnosed cancer and the third leading cause of cancer related deaths in men. With early detection, definitive therapeutic options can provide a cure. However, undetected extracapsular or regional lymph node metastasis plagues the long-term survival statistics of definitive therapies. In advanced prostate cancer, initial androgen depravation therapy has failed to control cancer progression, and regional lymph node and distant osseous metastasis are common. With metastatic spread, prostate cancer remains incurable. Aberrant expression of the bombesin subtype 2 receptor (BB2r) is present on over 80% of human prostate cancer tissues evaluated. The BB2r binds with high affinity to the bombesin peptide (BBN), stimulating agonist mediated receptor-peptide internalization into the cancer cell. Accordingly, targeting the BB2r with radioisotopes conjugated to BBN represents a promising method for diagnostic and therapeutic radiopharmaceutical development for metastatic prostate cancer. The results of this research demonstrate the potential diagnostic capabilities of BB2r targeted compounds. We also demonstrate a potential mechanism of therapeutic effect while optimizing administration timing, and evaluate the therapeutic potential of BB2r targeted radiotherapy administered with FDA approved, radiosensitizing chemotherapeutics for the treatment of metastatic prostate cancer. Taken together, BB2r targeted radiopharmaceuticals have the potential to fill a well known clinical need for the diagnosis and treatment of metastatic prostate cancer in human patients."],"dc:identifier.doi":["https://doi.org/10.32469/10355/10921"],"dc:identifier.uri":["https://hdl.handle.net/10355/10921"],"dc:language":["English"],"dc:language.iso":["eng"],"dc:publisher":["University of Missouri--Columbia"],"dc:rights":["Access to files is limited to the campuses of the University of Missouri with SSO login."],"dc:title":["Targeting the bombesin subtype 2 receptor for the diagnosis and treatment of metastatic prostate cancer"],"dc:type":["Thesis"],"thesis:degree_discipline":["Veterinary pathobiology (MU)"],"thesis:degree_level":["Doctoral"],"thesis:degree_name":["Ph. D."],"thesis:institution_name":["University of Missouri--Columbia"]},"updated_at":"2026-07-24T03:08:20Z"}